These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28410137)

  • 1. FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells
    Berahovich R; Xu S; Zhou H; Harto H; Xu Q; Garcia A; Liu F; Golubovskaya VM; Wu L
    Front Biosci (Landmark Ed); 2017 Jun; 22(10):1644-1654. PubMed ID: 28410137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells
    Valentine M; Li L; Zhou H; Xu S; Sun J; Liu C; Harto H; Berahovich R; Golubovskaya V; Wu L
    Front Biosci (Landmark Ed); 2020 Jan; 25(2):270-282. PubMed ID: 31585889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Nonviral
    Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
    Front Immunol; 2021; 12():802705. PubMed ID: 35082789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.
    Golubovskaya VM; Berahovich R; Xu Q; Zhou H; Xu S; Guan J; Harto H; Li L; Wu L
    Front Biosci (Landmark Ed); 2018 Jun; 23(12):2245-2254. PubMed ID: 29772559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 6. Versatile strategy for controlling the specificity and activity of engineered T cells.
    Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
    Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
    Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
    Sabatino M; Hu J; Sommariva M; Gautam S; Fellowes V; Hocker JD; Dougherty S; Qin H; Klebanoff CA; Fry TJ; Gress RE; Kochenderfer JN; Stroncek DF; Ji Y; Gattinoni L
    Blood; 2016 Jul; 128(4):519-28. PubMed ID: 27226436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
    Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
    Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
    Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system.
    Khaniya A; Rad SMAH; Halpin J; Tawinwung S; McLellan A; Suppipat K; Hirankarn N
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
    Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
    PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
    Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
    Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
    Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
    Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
    Tsukahara T; Ohmine K; Yamamoto C; Uchibori R; Ido H; Teruya T; Urabe M; Mizukami H; Kume A; Nakamura M; Mineno J; Takesako K; Riviere I; Sadelain M; Brentjens R; Ozawa K
    Biochem Biophys Res Commun; 2013 Aug; 438(1):84-9. PubMed ID: 23872144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.